“Sanofi-GSK’s vaccine is the first candidate to demonstrate efficacy in a placebo-controlled trial in an environment of high Omicron variant circulation,” Sanofi said in a statement. Sanofi’s Paris-listed shares and GSK’s London-listed shares were both up more than 1% in morning trading.
